MX2023005533A - Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. - Google Patents

Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.

Info

Publication number
MX2023005533A
MX2023005533A MX2023005533A MX2023005533A MX2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
medicine
application
dione derivative
Prior art date
Application number
MX2023005533A
Other languages
English (en)
Spanish (es)
Inventor
Hongbo Fei
Feng He
Weikang Tao
Xiaomin Zhang
Weimin Hu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023005533A publication Critical patent/MX2023005533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023005533A 2020-11-20 2021-11-19 Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. MX2023005533A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202011310827 2020-11-20
CN202110021509 2021-01-08
CN202110244090 2021-03-05
CN202110464375 2021-04-28
PCT/CN2021/131642 WO2022105852A1 (zh) 2020-11-20 2021-11-19 三嗪二酮类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023005533A true MX2023005533A (es) 2023-05-25

Family

ID=81708401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005533A MX2023005533A (es) 2020-11-20 2021-11-19 Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.

Country Status (10)

Country Link
US (1) US20240010639A1 (cg-RX-API-DMAC7.html)
EP (1) EP4249474A4 (cg-RX-API-DMAC7.html)
JP (2) JP7849587B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230110538A (cg-RX-API-DMAC7.html)
CN (4) CN119638681A (cg-RX-API-DMAC7.html)
AU (1) AU2021381664B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198934A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005533A (cg-RX-API-DMAC7.html)
TW (1) TW202227420A (cg-RX-API-DMAC7.html)
WO (1) WO2022105852A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) * 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
CN117088854A (zh) * 2022-05-20 2023-11-21 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法
WO2023222103A1 (zh) 2022-05-20 2023-11-23 江苏恒瑞医药股份有限公司 一种三嗪二酮类衍生物的晶型及制备方法
WO2024056096A1 (zh) * 2022-09-16 2024-03-21 江苏豪森药业集团有限公司 一种含氮杂环酮化合物的晶型及其制备方法
WO2026130464A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 制备治疗肥厚型心肌病药物的用途
WO2026153470A1 (zh) * 2025-01-16 2026-07-23 江苏恒瑞医药股份有限公司 制备治疗非梗阻性肥厚型心肌病药物的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5502089B2 (ja) * 2008-10-09 2014-05-28 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
SG173647A1 (en) * 2009-02-13 2011-10-28 Shionogi & Co Novel triazine derivative and pharmaceutical composition containing same
US20110319400A1 (en) * 2010-06-28 2011-12-29 Flores Christopher M Prokineticin 1 receptor antagonists for the treatment of pain
US9718790B2 (en) * 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) * 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
CN111094300B (zh) * 2018-01-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
MA53491A (fr) * 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途

Also Published As

Publication number Publication date
CA3198934A1 (en) 2022-05-27
AU2021381664A1 (en) 2023-06-15
JP2023550444A (ja) 2023-12-01
KR20230110538A (ko) 2023-07-24
CN116323598B (zh) 2024-11-15
CN119638680A (zh) 2025-03-18
EP4249474A4 (en) 2024-04-17
CN119638682A (zh) 2025-03-18
EP4249474A1 (en) 2023-09-27
WO2022105852A1 (zh) 2022-05-27
CN116323598A (zh) 2023-06-23
US20240010639A1 (en) 2024-01-11
AU2021381664B2 (en) 2026-05-28
JP2026097848A (ja) 2026-06-16
JP7849587B2 (ja) 2026-04-22
TW202227420A (zh) 2022-07-16
CN119638681A (zh) 2025-03-18

Similar Documents

Publication Publication Date Title
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0517426A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2010123028A (ru) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
PH12021551232A1 (en) Haloallylamine compounds and application thereof
WO2022079290A3 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
ZA202501471B (en) Preparation and use of quinazolinone derivative as kinase inhibitor
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
RU2013148817A (ru) Комбинации соединений-ингибиторов акт и мек и способы их применения
JOP20240217A1 (ar) مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
MX2023010673A (es) Cetonas heterociclicas que contienen nitrogeno, metodos de preparacion y usos medicinales de las mismas.
MX2026001837A (es) Compuestos que contienen ciclobutilo
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer